BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Deals

  Meihua International Medical Technologies Co., Ltd. Announces Pricing of $36,000,000 Initial Public Offering

  Meihua International Medical Technologies Co., Ltd. today announced the pricing of its initial public offering (the “Offering”) of 3,600,000 ordinary shares at a public offering price of $10.00 per ordinary share.

  February 16, 2022

   · 

  6 min read
• Business

  PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy

  PerkinElmer, Inc. today announced that its SIRION Biotech business have entered into an agreement to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas.

  February 16, 2022

   · 

  6 min read
• Pharm Country

  ProPhase Labs Announces Special Cash Dividend - Feb 16, 2022

  ProPhase Labs, Inc., a diversified biotech and genomics company, announced that its Board of Directors has declared a special cash dividend in the amount of $0.30 per share on its common stock, payable on March 10, 2022 to stockholders of record as of March 1, 2022.

  February 16, 2022

   · 

  4 min read
• Job Trends

  New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced results from a new analysis showing treatment with UPLIZNA effectively reduced the severity of attacks in people with NMOSD.

  February 16, 2022

   · 

  9 min read
• Biotech Bay

  Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research

  Better Therapeutics, Inc. today announced the first patient has been enrolled in a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001 for the treatment of type 2 diabetes.

  February 16, 2022

   · 

  5 min read
• Pharyngitis Diagnostic Market: Asia Pacific to Lead Global Market

  Pharyngitis is the medical condition that causes inflammation at the back of the throat which is known as pharynx.

  February 16, 2022

   · 

  5 min read
• Mechanical Circulatory Support Devices Market: Increase in incidence of cardiovascular diseases is expected to drive the market

  Mechanical circulatory support includes a range of therapies and devices which aid in rescuing patients from the life-threatening cardiogenic shock.

  February 16, 2022

   · 

  5 min read
• Oxaliplatin Market: Adjuvant Treatment of Stage III Colon Cancer Segment to Account for Major Share of Global Market

  Oxaliplatin is anti-cancer medication indicated to treat colorectal cancer. It is a platinum-based drug belonging to the same family as that of cisplatin and carboplatin.

  February 16, 2022

   · 

  5 min read
• Fetal and Neonatal Heart Monitor Market: Rise in Cases of Preterm Birth Due to Premature Rupture of Membrane is Expected to Drive the Market

  The heart and the circulatory systems followed by the nervous system is formed at the earliest stages of Fetus.

  February 16, 2022

   · 

  4 min read
• The Oncology Biosimilars Market is Looking to Expand at a Stellar CAGR of 29.4% by 2025 end

  Fact.MR – A Market research and competitive intelligence provider: The global oncology biosimilars market is projected to expand at a market size at a CAGR of 29.4% by 2025 end.

  February 16, 2022

   · 

  6 min read